People · Operator
Named in public records as an officer, director or promoter · active 2022–2024 · Biotechnology, Software / Tech
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ventus Therapeutics U.S., Inc. | — | Biotechnology | Series C | $186.8M | $1.6B | 2022 |
| Latent Labs Technologies, Inc. | — | Software / Tech | Series B | $49.0M | $253.7M | 2023 |
| Brumby Systems, Inc. | — | Software / Tech | Seed | $2.0M | $21.9M | 2022 |
John Cassidy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside John Cassidy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jerel Davis | 1 | 13 |
| Josh Resnick | 1 | 7 |
| Hao Wu | 1 | 5 |
| Steven James | 1 | 3 |
| James McHugh | 1 | 3 |
| Jane Pritchett Henderson | 1 | 3 |
| Markus Warmuth | 1 | 3 |
| Daniel Koerwer | 1 | 2 |
| Brendan Bulik-Sullivan | 1 | 2 |
| Michael Mc Cannon | 1 | 1 |
| Simon Kohl | 1 | 1 |
| Michael Crackower | 1 | 1 |
| Tony Kulesa | 1 | 1 |
| Marcelo Bigal | 1 | 1 |
| Dolca Thomas | 1 | 1 |
| Zachary McNealy | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.